10 Firms Shining Bright in a Bleeding Market

7. Ocular Therapeutix Inc. (NASDAQ:OCUL)

Ocular Therapeutix rallied for a second day on Monday, adding 5.22 percent to finish at $11.89 apiece as investors repositioned portfolios ahead of two healthcare conferences in the next few days.

Last week, Ocular Therapeutix Inc. (NASDAQ:OCUL) said that its chairman, president, and CEO, Pravin Dugel, would participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, as well as the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025. Investors are expected to closely watch out for cues about the company’s pipeline developments and outlook.

Earlier this month, Ocular Therapeutix Inc. (NASDAQ:OCUL) widened its net loss by 90 percent to $69.4 million from $36.49 million in the same period last year.

Revenues also dropped by 5.8 percent to $14.5 million from $15.4 million year-on-year, due to a significantly more challenging reimbursement environment for its eye treatment, Dextenza, in 2025.